Related Experiment Videos
Anticoagulant treatment of atrial fibrillation in the elderly
1Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City 66103.
Insights
Low-dose warfarin is the recommended treatment for elderly patients with non-valvular atrial fibrillation. Denying this therapy based on age alone poses significant risks of thromboembolic complications.
Area of Science:
- Geriatric Medicine
- Cardiology
- Pharmacology
Background:
- Non-valvular atrial fibrillation (NVAF) poses a significant stroke risk in the elderly.
- Age alone should not be a barrier to appropriate anticoagulation therapy.
Purpose of the Study:
- To establish the optimal treatment strategy for elderly patients diagnosed with non-valvular atrial fibrillation.
- To highlight the risks associated with withholding anticoagulation in this demographic.
Main Methods:
- Review of existing clinical evidence and treatment guidelines.
- Analysis of patient outcomes related to anticoagulation therapy in elderly NVAF patients.
Main Results:
- Low-dose warfarin is clinically evidenced as the most appropriate treatment for elderly patients with NVAF.
- Contraindications to warfarin exist but should not lead to age-based denial of treatment.
Conclusions:
- Elderly patients with NVAF should receive low-dose warfarin treatment.
- Withholding anticoagulation based solely on age increases the risk of severe thromboembolic events.
Abstract:
There is now adequate clinical evidence that the most appropriate treatment of elderly patients with non-valvular atrial fibrillation is with low dose warfarin. Patients may have contraindications to therapy with this agent, but should not be denied treatment based on age alone. Withholding treatment based on age places patients at unwarranted risk for severely disabling thromboembolic complications.